3-(4-methylpiperazin-1-yl)propyl-isopropylamine | 1042528-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-(4-methylpiperazin-1-yl)propyl-isopropylamine
• 英文别名: [3-(4-Methylpiperazin-1-yl)propyl](propan-2-yl)amine；3-(4-methylpiperazin-1-yl)-N-propan-2-ylpropan-1-amine
• CAS: 1042528-70-0
• 化学式: C₁₁H₂₅N₃
• mdl: MFCD11160128
• 分子量: 199.34
• InChiKey: YJAJULNXPNZYQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-methylpiperazin-1-yl)propyl-isopropylamine 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists

  摘要：

  The discovery of a novel series of 8-azabicyclo[3.2.1] octan-3-yl)-3-(4-chlorophenyl) propanamide antagonists of the vasopressin V-1A receptor is disclosed. Compounds 47 and 48 were found to be high affinity, selective vasopressin V-1A antagonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.096

文献信息

• Kinase Inhibitors
  申请人：Wurster A. Julie

  公开号：US20070032478A1

  公开（公告）日：2007-02-08

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调节、调控和/或抑制异常细胞增殖。
• Small Molecule Inhibitors of Toll-Like Receptor 9
  申请人：Lipford Grayson B.

  公开号：US20100160314A1

  公开（公告）日：2010-06-24

  Small molecule compounds and compositions containing said compounds useful for inhibiting signaling by certain Toll-like receptors (TLRs), particularly TLR9, are provided. The compounds and compositions can be used to inhibit immune responses, including unwanted immune responses in particular. Compounds, compositions, and methods are provided to treat a variety of conditions involving unwanted immune responses, including for example autoimmune disease, inflammation, transplant rejection, and sepsis.

  提供小分子化合物和包含所述化合物的组合物，用于抑制某些Toll样受体（TLRs）的信号传导，特别是TLR9。这些化合物和组合物可用于抑制免疫反应，包括特别是非所需的免疫反应。提供的化合物、组合物和方法可用于治疗涉及非所需免疫反应的各种病症，例如自身免疫病、炎症、移植排斥和败血症。
• CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
  申请人：LEHMANN-LINTZ Thorsten

  公开号：US20110217311A1

  公开（公告）日：2011-09-08

  The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2 a or Mnk2 b ) and/or variants thereof.

  本发明涉及新型噻吩并嘧啶化合物，其一般公式，包含这些化合物的药物组合物，以及它们在预防和/或治疗可通过抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）及其变体的激酶活性而影响的疾病中的治疗用途。
• [EN] TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS ANTAGONISTES DU RÉCEPTEUR DE TYPE TOLL ET LEURS MÉTHODES D'UTILISATION
  申请人：DYNAVAX TECH CORP

  公开号：WO2018089695A1

  公开（公告）日：2018-05-17

  The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.

  该发明涉及以下式（I）的化合物：或其盐或溶剂化合物，其中变量如本文所述。式（I）的化合物及其药物组合物是Toll样受体拮抗剂，如TLR7、TLR8和/或TLR9，可用于抑制免疫反应并治疗与不良免疫反应相关的疾病。
• Indenoisoquinolinone analogs and methods of use thereof
  申请人：Jagtap Prakash

  公开号：US20070049555A1

  公开（公告）日：2007-03-01

  The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.

  本发明涉及Indenoisoquinolinone类似物，包括有效量的Indenoisoquinolinone类似物的组合物，以及用于治疗或预防炎症性疾病、再灌注损伤、糖尿病、糖尿病并发症、器官移植引起的再氧化损伤、缺血状况、神经退行性疾病、肾功能衰竭、血管疾病、心血管疾病、癌症、早产并发症、心肌病、视网膜病、肾病、神经病、勃起功能障碍或尿失禁的方法，包括向需要治疗的受体内给予有效量的Indenoisoquinolinone类似物。